X4 Pharmaceuticals (NASDAQ:XFOR) Raised to Hold at Wall Street Zen

X4 Pharmaceuticals (NASDAQ:XFOR) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other equities analysts have also recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of X4 Pharmaceuticals in a report on Monday, December 29th. Stifel Nicolaus set a $10.00 price target on X4 Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, December 5th. Guggenheim assumed coverage on X4 Pharmaceuticals in a report on Monday, March 9th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Zacks Research lowered shares of X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 26th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $28.88.

X4 Pharmaceuticals Stock Performance

Shares of X4 Pharmaceuticals stock opened at $4.28 on Friday. The company’s 50 day moving average price is $3.67 and its two-hundred day moving average price is $3.62. The firm has a market capitalization of $389.14 million, a P/E ratio of -0.99 and a beta of 0.43. X4 Pharmaceuticals has a fifty-two week low of $1.35 and a fifty-two week high of $9.56. The company has a debt-to-equity ratio of 0.41, a current ratio of 10.16 and a quick ratio of 5.48.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings results on Tuesday, March 24th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.14. X4 Pharmaceuticals had a negative net margin of 225.55% and a negative return on equity of 115.27%. The company had revenue of $2.57 million during the quarter, compared to the consensus estimate of $1.68 million. On average, equities analysts forecast that X4 Pharmaceuticals will post -0.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On X4 Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in XFOR. Indivisible Partners acquired a new position in X4 Pharmaceuticals in the fourth quarter valued at approximately $40,000. Squarepoint Ops LLC bought a new stake in shares of X4 Pharmaceuticals in the 4th quarter valued at $50,000. Two Sigma Investments LP bought a new stake in shares of X4 Pharmaceuticals in the 3rd quarter valued at $47,000. Stifel Financial Corp acquired a new position in shares of X4 Pharmaceuticals during the 4th quarter valued at $82,000. Finally, Virtu Financial LLC bought a new position in X4 Pharmaceuticals during the fourth quarter worth $90,000. 72.03% of the stock is currently owned by institutional investors.

More X4 Pharmaceuticals News

Here are the key news stories impacting X4 Pharmaceuticals this week:

• Positive Sentiment: Brookline materially improved its FY2026 EPS view (from -$1.50 to -$1.04), a smaller near‑term loss that suggests a faster path toward profitability. Brookline Cap M FY2026 estimate
• Positive Sentiment: Brookline raised its FY2027 EPS forecast (from -$1.70 to -$0.96), reducing multi‑year downside and improving the medium‑term outlook. Brookline Cap M FY2027 estimate
• Positive Sentiment: Brookline lifted its FY2028 estimate (from -$0.42 to -$0.24), another sign of improving expected margins in later years. Brookline Cap M FY2028 estimate
• Positive Sentiment: Brookline published a long‑range FY2030 EPS projection of $2.85, signaling significant upside potential if X4 hits longer‑term commercialization and scaling assumptions. Brookline Cap M FY2030 estimate
• Neutral Sentiment: Brookline provided updated quarterly EPS forecasts for 2026 (Q1: -$0.20, Q2: -$0.23, Q3: -$0.27, Q4: -$0.34) that set expectations for near‑term performance but are routine analyst guidance updates rather than company‑driven news. Brookline Cap M quarterly estimates
• Negative Sentiment: Brookline cut its FY2029 EPS forecast sharply (from $1.52 to $0.85), lowering medium‑term upside and indicating the analyst reduced confidence in the timing/scale of revenue or margin improvements for that year. Brookline Cap M FY2029 revision

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.